Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 4/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637125 | 0.94 | CXCR4 (0.41) | CXCR4DRD2 | |
| SCHEMBL15161928 | 0.94 | CXCR4 (0.43) | CXCR4LTA4H | |
| SCHEMBL1638396 | 0.93 | CXCR4 (0.43) | CXCR4LTA4H | |
| SCHEMBL2189971 | 0.93 | CXCR4 (0.45) | CXCR4DRD2LTA4HTAAR1CTSD | |
| SCHEMBL1637858 | 0.93 | CXCR4 (0.42) | CXCR4DRD2CTSD | |
| SCHEMBL1636379 | 0.92 | CXCR4 (0.45) | CXCR4TAAR1CTSDBCHE | |
| SCHEMBL1638097 | 0.92 | CXCR4 (0.47) | CXCR4TAAR1CTSDBCHE | |
| SCHEMBL1636318 | 0.92 | CXCR4 (0.44) | CXCR4CTSD | |
| SCHEMBL15161965 | 0.92 | CXCR4 (0.42) | CXCR4 | |
| SCHEMBL15162492 | 0.92 | CXCR4 (0.43) | CXCR4LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | claimed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | claimed |
| US-8722719-B2 | Amine compound and use for same | KUREHA CORPORATION (JP) | 2014-05-13 | — | — | US | disclosed |
| EP-1724263-B1 | BASIC AMINE COMPOUND AND USE THEREOF | KUREHA CORP (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20130245280-A1 | AMINE COMPOUND AND USE FOR SAME | KUREHA CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| EP-2626349-A1 | AMINE COMPOUND AND USE FOR SAME | Kureha Corporation (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | CXCR4 86/4885DRD2 175/4885LTA4H 4574/4885 |
| US-20130245280-A1 | AMINE COMPOUND AND USE FOR SAME | SAT1, ALDH7A1, HNMT | CXCR4 4194/4885DRD2 829/4885LTA4H 787/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | CXCR4 100/4885DRD2 257/4885LTA4H 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.